美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Seaport Therapeutics

24.70

+1.365.83%

盤後：24.700.00000.00%19:30 EDT

成交量：17.42萬

成交額：429.10萬

市值：13.22億

市盈率：-9.82

高：25.37

開：23.33

低：23.33

收：23.34

52周最高：28.38

52周最低：14.85

股本：5,353.06萬

流通股本：1,416.00萬

量比：1.03

換手率：1.23%

股息：- -

股息率：- -

每股收益(TTM):-2.5160

每股收益(LYR):-10.0430

淨資產收益率：-28.08%

總資產收益率：-18.90%

市淨率：3.13

市盈率(LYR):-2.46

資料載入中...

總覽公司新聞資訊公告

Seaport Therapeutics啓動Glyphallo Phase 2B臨床試驗Buoy-1入組，頂線數據預計2027年上半年揭曉

Seaport Therapeutics公布Glyphallo™健康志願者1期駕駛模擬試驗積極頂線結果

Seaport Therapeutics發布2026年第二季度財務業績，並強調近期企業與臨床進展

Seaport Therapeutics 獲 H.C. Wainwright 首次覆蓋，給予買入評級及50美元目標價

Seaport Therapeutics公布2026年第一季度財務業績並強調近期公司及臨床進展

Seaport Therapeutics - 七日Glyphago給藥實現治療性阿戈美拉汀暴露，無肝酶升高

Seaport Therapeutics公布Glyphago™在健康受試者中1期概念驗證試驗的多次遞增劑量積極數據

Seaport Therapeutics - Glyphago重複給藥顯示良好安全性且無肝臟相關不良事件

Seaport Therapeutics將出席兩大投資者會議，聚焦神經精神藥物研發

环球市场播报

美國研究綜述-阿波羅、菲利普斯66、瓦萊羅能源

神經精神治療藥物開發商Seaport(SPTX.US)IPO定價16-18美元/股擬籌資2.01億美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/SPTX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SPTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPTX\",,,,,undefined,":{"symbol":"SPTX","market":"US","secType":"STK","nameCN":"Seaport Therapeutics","latestPrice":24.7,"timestamp":1789416000000,"preClose":23.34,"halted":0,"volume":174188,"hourTrading":{"tag":"盘后","latestPrice":24.7,"preClose":24.7,"latestTime":"19:30 EDT","volume":929,"amount":22946.3,"timestamp":1789428600393,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.05826906598114822,"floatShares":14160000,"shares":53530550,"eps":-2.516,"marketStatus":"盤後交易","change":1.36,"latestTime":"09-14 19:51:32 EDT","open":23.33,"high":25.37,"low":23.33,"amount":4291014.080192,"amplitude":0.087404,"askPrice":25.18,"askSize":79,"bidPrice":24.22,"bidSize":83,"shortable":3,"etf":0,"ttmEps":-2.516,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"listingDate":1777608000000,"exchange":"NASDAQ","adjPreClose":23.34,"postHourTrading":{"tag":"盘后","latestPrice":24.7,"preClose":24.7,"latestTime":"19:30 EDT","volume":929,"amount":22946.3,"timestamp":1789428600393,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.034732},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPTX\",,,,,undefined,":{"symbol":"SPTX","floatShares":14160000,"roa":"-18.90%","roe":"-28.08%","lyrEps":-10.043037,"volumeRatio":1.034732,"shares":53530550,"dividePrice":0,"high":25.37,"amplitude":0.087404,"preClose":23.34,"low":23.33,"week52Low":14.85,"pbRate":"3.13","week52High":28.3833,"institutionHeld":0,"latestPrice":24.7,"committee":0.024691,"eps":-2.516,"divideRate":0,"volume":174188,"delay":0,"ttmEps":-2.516,"open":23.33,"prevYearClose":18,"prevWeekClose":23.34,"prevMonthClose":23.68,"prevQuarterClose":21.72,"fiveDayClose":24.86,"twentyDayClose":24.22,"sixtyDayClose":17.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-03","symbol":"SPTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1785729600000,"reportTimeType":"pre","actualEps":-1.78}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.4286,"hold":0.1429,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4286,"analysts":7,"updateTime":1787889600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SPTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SPTX","date":"2026-09-11","current":-9.81717,"percent":0.977528,"low":-14.505892,"twenty":-12.759648,"median":-11.944292,"eighty":-9.835946,"high":-8.644409,"avg":-11.623865,"sd":1.408566,"marketCap":1246191204},"quantilePoints":[{"date":"2026-05-08","current":-10.976498,"twenty":-12.440976,"median":-11.330579,"eighty":-11.259763,"marketCap":821931163},{"date":"2026-05-15","current":-11.99625,"twenty":-12.004748,"median":-11.348283,"eighty":-11.231436,"marketCap":898291219},{"date":"2026-05-22","current":-12.173291,"twenty":-12.004748,"median":-11.330579,"eighty":-11.135126,"marketCap":911548174},{"date":"2026-05-29","current":-13.31343,"twenty":-12.537286,"median":-11.684659,"eighty":-11.163453,"marketCap":996922959},{"date":"2026-06-05","current":-12.661922,"twenty":-12.698746,"median":-12.017495,"eighty":-11.247016,"marketCap":948137367},{"date":"2026-06-12","current":-12.548616,"twenty":-12.593938,"median":-12.03874,"eighty":-11.316416,"marketCap":939652917},{"date":"2026-06-18","current":-10.501726,"twenty":-12.6166,"median":-12.03874,"eighty":-11.222938,"marketCap":915372405},{"date":"2026-06-26","current":-11.889673,"twenty":-12.53162,"median":-11.895161,"eighty":-11.165224,"marketCap":1036351448},{"date":"2026-07-02","current":-13.173217,"twenty":-12.752567,"median":-12.017495,"eighty":-11.198861,"marketCap":1148230297},{"date":"2026-07-10","current":-12.595929,"twenty":-12.752567,"median":-12.03874,"eighty":-11.215593,"marketCap":1097911580},{"date":"2026-07-17","current":-11.987935,"twenty":-12.752567,"median":-12.12726,"eighty":-11.302253,"marketCap":1044916336},{"date":"2026-07-24","current":-13.474144,"twenty":-12.866109,"median":-12.187454,"eighty":-11.330579,"marketCap":1174460267},{"date":"2026-07-31","current":-12.479243,"twenty":-12.804736,"median":-12.201617,"eighty":-11.330579,"marketCap":1087740776},{"date":"2026-08-07","current":-14.1804,"twenty":-12.896856,"median":-12.347233,"eighty":-11.365987,"marketCap":1236020399},{"date":"2026-08-14","current":-9.423399,"twenty":-12.896856,"median":-12.221306,"eighty":-11.295171,"marketCap":1269209340},{"date":"2026-08-21","current":-9.552568,"twenty":-12.881452,"median":-12.180373,"eighty":-11.146457,"marketCap":1286606769},{"date":"2026-08-28","current":-10.432907,"twenty":-12.804736,"median":-12.123719,"eighty":-11.036024,"marketCap":1405176937},{"date":"2026-09-04","current":-9.653917,"twenty":-12.782309,"median":-12.017495,"eighty":-10.432907,"marketCap":1300257059},{"date":"2026-09-11","current":-9.252498,"twenty":-12.759648,"median":-11.944292,"eighty":-9.835946,"marketCap":1246191204}],"updateTime":1789429892799},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPTX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1118717252","title":"Seaport Therapeutics啓動Glyphallo Phase 2B臨床試驗Buoy-1入組，頂線數據預計2027年上半年揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=1118717252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118717252?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:01","pubTimestamp":1788951675,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics宣布，其Glyphallo药物的Buoy-1 Phase 2B临床试验已正式开启患者入组工作。该公司预计，该试验的顶线数据将于2027年上半年公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140238334","title":"Seaport Therapeutics公布Glyphallo™健康志願者1期駕駛模擬試驗積極頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1140238334","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140238334?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:01","pubTimestamp":1788951674,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics宣布，其针对Glyphallo™在健康志愿者中开展的1期驾驶模拟试验，已取得积极的顶线结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142309956","title":"Seaport Therapeutics發布2026年第二季度財務業績，並強調近期企業與臨床進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1142309956","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142309956?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 19:01","pubTimestamp":1785754872,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics近日公布了其2026年第二季度的财务报告，同时着重强调了公司在企业运营及临床开发方面的最新进展。这份公告不仅涵盖了关键的财务数据，还详细披露了公司近期取得的里程碑式成就，为投资者提供了全面的业务更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123404378","title":"Seaport Therapeutics 獲 H.C. Wainwright 首次覆蓋，給予買入評級及50美元目標價","url":"https://stock-news.laohu8.com/highlight/detail?id=1123404378","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123404378?lang=zh_tw&edition=fundamental","pubTime":"2026-07-15 18:11","pubTimestamp":1784110277,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics 获得了 H.C. Wainwright 的首次关注，该机构对其启动了覆盖研究，并给出了积极的“买入”评级。分析师团队为这家生物制药公司设定了50美元的目标股价，预示着对其未来增长潜力的坚定看好。此举标志着资本市场对该公司研发管线与商业前景的进一步认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136030739","title":"Seaport Therapeutics公布2026年第一季度財務業績並強調近期公司及臨床進展","url":"https://stock-news.laohu8.com/highlight/detail?id=1136030739","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136030739?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 19:05","pubTimestamp":1780916727,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics公布了其2026年第一季度的财务业绩，并重点介绍了近期的公司运营与临床研发进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159152611","title":"Seaport Therapeutics - 七日Glyphago給藥實現治療性阿戈美拉汀暴露，無肝酶升高","url":"https://stock-news.laohu8.com/highlight/detail?id=1159152611","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159152611?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 19:04","pubTimestamp":1780916669,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics宣布，其为期七天的Glyphago给药方案成功达到了治疗所需的阿戈美拉汀暴露水平，且未观察到肝酶升高的现象。这一进展标志着公司在探索更安全、有效的给药策略上取得了重要突破。\n研究数据表明，该给药方案在维持有效血药浓度的同时，有效规避了此前同类疗法中常见的肝脏安全性问题。这一发现为阿戈美拉汀相关疗法的后续开发提供了关键的安全性和有效性数据支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133710650","title":"Seaport Therapeutics公布Glyphago™在健康受試者中1期概念驗證試驗的多次遞增劑量積極數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1133710650","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133710650?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 19:02","pubTimestamp":1780916559,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics公布了其候选药物Glyphago™在健康受试者中进行的1期概念验证试验的多次递增剂量数据，结果积极。\n该试验旨在评估Glyphago™在多次递增剂量下的安全性、耐受性及药代动力学特征。数据显示，在试验的剂量范围内，药物表现出良好的耐受性，未出现严重不良事件。同时，药代动力学参数符合预期，支持进一步的临床开发。\n这些积极的初步数据为Glyphago™后续在目标患者群体中的研究奠定了基础。公司计划基于这些结果推进该项目的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189804894","title":"Seaport Therapeutics - Glyphago重複給藥顯示良好安全性且無肝臟相關不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1189804894","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189804894?lang=zh_tw&edition=fundamental","pubTime":"2026-06-08 19:02","pubTimestamp":1780916551,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics宣布，其Glyphago药物的重复给药研究显示出良好的安全性特征，且未观察到与肝脏相关的不良事件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640954794","title":"Seaport Therapeutics將出席兩大投資者會議，聚焦神經精神藥物研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2640954794","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640954794?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 21:09","pubTimestamp":1780319340,"startTime":"0","endTime":"0","summary":"Seaport Therapeutics是一家专注于开发新型神经精神疾病疗法的临床阶段生物制药公司，近日宣布其管理团队将参与两场即将举行的投资者会议。　　根据公司发布的消息，Seaport将出席高盛第47届年度全球医疗保健会议，炉边谈话定于2026年6月10日上午8点举行。　　Seaport Therapeutics总部位于马萨诸塞州波士顿，于2024年成立，2026年5月1日在纳斯达克完成IPO上市，股票代码为SPTX。此次参与两大投资者会议，Seaport将向投资界分享其在神经精神药物研发领域的最新进展与战略规划。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-01/doc-inhzxmef5038397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4539","BK4139","SPTX","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638473599","title":"美國研究綜述-阿波羅、菲利普斯66、瓦萊羅能源","url":"https://stock-news.laohu8.com/highlight/detail?id=2638473599","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638473599?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 15:32","pubTimestamp":1779780727,"startTime":"0","endTime":"0","summary":"美国研究综述-阿波罗、菲利普斯66、瓦莱罗能源路透5月26日 - 周二，华尔街证券分析师调整了多家在美国上市公司的评级和目标股价，其中包括阿波罗、菲利普斯66和瓦莱罗能源。股票条目按字母顺序排列。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nL4T4230EH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","LU0205194284.USD","BK4585","LU0456854461.SGD","PS","TDS","ALB","LU0345780950.USD","LU1206713676.USD","ALNT","IE00B19Z3581.USD","LU2095319765.USD","BK4157","LU0300736062.USD","IE00B775SV38.USD","LU1861214812.USD","BK4139","LU0630314457.HKD","BAH","CGNX","RRX","TTAN","PSX","COAG","LU1201861249.SGD","LU1169589451.USD","BK4138","BK4548","BJ","LU0980610538.SGD","LU1803068623.USD","HLIO","LU0170899867.USD","VLO","SPTX","LU0477156953.USD","LU0130517989.USD","ALBG","TKR","LU0266512127.USD","MPC","APO","LU0096364046.USD","AD","LU0266013472.USD","LU2106854487.HKD","LU0274383776.USD","BK4155","IE00BZ1G4Q59.USD","LU0266512473.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630375655","title":"神經精神治療藥物開發商Seaport(SPTX.US)IPO定價16-18美元/股 擬籌資2.01億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630375655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630375655?lang=zh_tw&edition=fundamental","pubTime":"2026-04-28 16:08","pubTimestamp":1777363680,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于开发神经精神适应症疗法的生物科技公司Seaport Therapeutics周一公布了其首次公开募股条款。该公司计划以每股16-18美元的价格发行1180万股股票，筹资2.01亿美元。该公司预计于本周确定IPO发行价。据悉，Seaport Therapeutics是一家临床阶段的生物科技公司，致力于开发治疗神经精神疾病的口服疗法。此外，公司还有针对抑郁症及相关中枢神经系统疾病的临床前候选药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435201.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SPTX","IPOS","UUP","UDN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}